Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3336209 | Transfusion and Apheresis Science | 2007 | 8 Pages |
Abstract
Transplant-associated microangiopathy (TAM) is a severe complication following allogeneic hematopoietic stem cell transplantation (HSCT) even after reduced-intensity conditioning (RIC).Data on 112 patients following RIC were analyzed with respect to TAM according to the ASBMT and risk factors, response to well-defined therapy and outcome were determined.TAM occurred in 11 of 112 patients. Univariate analysis determined acute graft-versus-host disease and ABO-incompatibility as risk factors for TAM. Treatment consisted of withdrawal of calcineurin inhibitors and plasma exchange (PE). Response to PE was 64%. PE seems to be an effective therapeutic option that should be assessed in larger patient cohorts.
Related Topics
Health Sciences
Medicine and Dentistry
Hematology
Authors
Nina Worel, Hildegard T. Greinix, Gerda Leitner, Margit Mitterbauer, Werner Rabitsch, Agatha Rosenmayr, Paul Höcker, Peter Kalhs,